anti-mesothelin CAR T-cells (Chinese PLA General Hospital)

This investigational autologous chimeric antigen receptor (CAR) T-cell therapy targets mesothelin (MSLN), a cell-surface glycoprotein overexpressed in various solid tumors including mesothelioma, pancreatic, and ovarian cancers. Developed by the Chinese PLA General Hospital in collaboration with Gracell Biotechnologies, the therapy involves genetically engineering a patient's own T cells to recognize and eliminate MSLN-expressing malignant cells. Advanced versions of the therapy, such as GC008t and MPTK-CAR-T, utilize CRISPR-Cas9 technology to disrupt the Programmed cell death protein 1 (PD-1) gene and the T-cell receptor (TCR) to enhance T-cell persistence, reduce exhaustion, and potentially allow for donor-derived applications. Clinical evaluation is primarily focused on safety and feasibility in patients with relapsed or refractory advanced malignancies.

Other names

anti-meso-CAR vector transduced T cellsCART-meso cellsmesothelin-targeted CAR-T cellsanti-mesothelin CAR T-cells-Chinese PLA General Hospital-malignant mesothelioma-pancreatic cancer-ovarian cancer-triple negative breast cancer-endometrial cancer